A trial of early antiretrovirals and isoniazid preventive therapy in Africa

New England Journal of Medicine

Volumn 373, Issue 9, 2015, Pages 808-822

  Danel, Christine ^a   Moh, Raoul ^b   Gabillard, Delphine ^c   Badje, Anani ^d   Le Carrou, Jérôme ^e   Ouassa, Timothée ^f   Ouattara, Eric ^a   Anzian, Amani ^g   Ntakpé, Jean Baptiste ^a   Minga, Albert ^h   Kouame, Gérard M ⁱ   Bouhoussou, Franck ^j   Emieme, Arlette ^k   Kouamé, Antoine ^b   Inwoley, André ^b   Toni, Thomas D'Aquin ^b   Ahiboh, Hugues ^l   Kabran, Mathieu ^c   Rabe, Cyprien ^c   Sidibé, Baba ^d   Nzunetu, Gustave ^e   Konan, Romuald ^m   Gnokoro, Joachim ⁿ   Gouesse, Patrice ⁿ   Messou, Eugène ^b   Dohoun, Lambert ^c   Kamagate, Synali ^d,o   Yao, Abo ^d   Amon, Solange ^e   Kouame, Amadou Barenson ^d   Koua, Aboli ^p   Kouamé, Emmanuel ^l,m   Ndri, Yao ^s   Ba Gomis, Olivier ^q   Daligou, Marcelle ^q   Ackoundzé, Simplice ^k,l,n   Hawerlander, Denise ^k,l,m   Ani, Alex ^k,l,m   Dembéle, Fassery ^k,l,m   Koné, Fatoumata ^r   Guéhi, Calixte ^h,i   Kanga, Constance ^d,e,f   Koule, Serge ^e,f,g   Séri, Jonas ^f,g,h   Oyebi, Mykayila ^b,c,d   Mbakop, Nathalie ^e,f   Makaila, Olewole ^s   Babatunde, Carole ^a,b,d   Babatounde, Nathanael ^c,e   Bleoué, Gisèle ^d   Tchoutedjem, Mireille ^e   Kouadio, Alain Claude ^f   Sena, Ghislaine ^t   Yededji, Sahinou Yediga ^u   Assi, Rodrigue ^v   Bakayoko, Alima ^g   Mahassadi, Alassane ^h   Attia, Alain ^w   Oussou, Armel ^b   Mobio, Max ^x   Bamba, Doféré ^y   Koman, Mesmin ^e,k   Horo, Apollinaire ^j,k   Deschamps, Nina ^m   Chenal, Henri ⁿ   Sassan Morokro, Madeleine ^p   Konate, Seidou ^a   Aka, Kakou ^f   Aoussi, Eba ^b,c,d   Journot, Valérie ^c,d,e   Nchot, Célestin ^d,e   Karcher, Sophie ^l   Chaix, Marie Laure ^m   Rouzioux, Christine ⁿ   Sow, Papa Salif ^o   Perronne, Christian ^p   Girard, Pierre Marie ^a   Menan, Hervé ^c   Bissagnene, Emmanuel ^d   Kadio, Auguste ^e   Ettiegne Traore, Virginie ^f   Moh Semdé, Corinne ^g   Kouame, Abo ^g   Massumbuko, Jean Marie ^h   Chêne, Geneviève ^h   Dosso, Mireille ^b   Domoua, Serge K ^c   N'Dri Yoman, Thérèse ^e   Salamon, Roger ^f   Eholié, Serge P ^g,y   Anglaret, Xavier ^z   more..

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Centre Hospitalier Universitaire (CHU)   (United States)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f Programme PAC CI Agence Nationale de Recherches sur le SIDA Research Site   (France)

^g Centre de Diagnostic et de Recherches sur le SIDA   (France)

^h Serv Maladies Infect Tropicales A   (France)

ⁱ Service de Pneumologie   (France)

^j Service d'Otorhino Laryngologie   (France)

^k centre hospitalier de Boulogne sur Mer   (France)

^l Service de gynécologie   (France)

^m BP V3   (France)

ⁿ Centre Intégré de Recherche Bioclinique d'Abidjan   (Côte d’Ivoire)

^o Unité de Soins Ambulatoire et de Conseil   (France)

^p Centre la Pierre Angulaire   (France)

^q Centre de Prise en Charge et de Formation   (France)

^r Service de Gastro entéro hépatologie   (France)

^s CHU de Yopougon   (France)

^t HÔPITAL DU BOCAGE   (France)

^u Formation Sanitaire Urbaine Communautaire d'Anonkoua Kouté   (Côte d’Ivoire)

^v Hôpital El Rapha   (Gabon)

^w Programme National de Lutte Contre le SIDA   (Côte d’Ivoire)

^x Ensemble Pour Une Solidarité Thérapeutique   (France)

^y INSTITUT PASTEUR DE CÔTE D'IVOIRE   (Côte d’Ivoire)

^z Service de Dermatologie du CHU de Bouaké   (Côte d’Ivoire)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ISONIAZID; LAMIVUDINE; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT; VIRUS RNA;

ADULT; AFRICA; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FACTORIAL DESIGN; FEMALE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TUBERCULOSIS; VIRUS LOAD; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ASYMPTOMATIC DISEASE; CLINICAL TRIAL; COTE D'IVOIRE; FOLLOW UP; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; TIME TO TREATMENT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; ASYMPTOMATIC DISEASES; CD4 LYMPHOCYTE COUNT; COTE D'IVOIRE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; ISONIAZID; MALE; MIDDLE AGED; RNA, VIRAL; TIME-TO-TREATMENT; TUBERCULOSIS; VIRAL LOAD;

EID: 84940566834     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1507198     Document Type: Article

References (42)

1. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization (http://www.who.int/hiv/pub/arv/adult2010/en).
2. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: World Health Organization (http://www.who.int/hiv/pub/guidelines/arv2013/en).
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
4. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363:257-65.
5. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretrovi-ral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-44.
6. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203: 1637-46.
7. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
8. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995; 333: 845-51.
9. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012; 54: 714-23.
10. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993;7:1569-79.
11. Rana FS, Hawken MP, Mwachari C, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000;24:23-9.
12. Wong EB, Omar T, Setlhako GJ, et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS One 2012;7(10):e47542.
13. Cox JA, Lukande RL, Nelson AM, et al. An autopsy study describing causes of death and comparing clinico-pathologi-cal findings among hospitalized patients in Kampala, Uganda. PLoS One 2012; 7(3): e33685.
14. Martinson NA, Karstaedt A, Venter WD, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007; 21:2043-50.
15. Corbett EL, Churchyard GJ, Chara-lambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34: 1251-8.
16. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tu-berc Lung Dis 2002; 6: 55-63.
17. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9(7):e1001270.
18. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009;373:48-57.
19. Kufa T, Mngomezulu V, Charalam-bous S, et al. Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isonia-zid preventive therapy, and infection control. J Acquir Immune Defic Syndr 2012; 60(2):e22-e28.
20. Lester R, Hamilton R, Charalambous S, et al. Barriers to implementation of iso-niazid preventive therapy in HIV clinics: a qualitative study. AIDS 2010; 24: Suppl 5: S45-S48.
21. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011;8(1):e1000391.
22. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained setting. Geneva: World Health Organization (http://whqlibdoc.who.int/publications/2011/9789241500708-eng.pdf).
23. Ouattara E, Danel C, Moh R, et al. Early upper digestive tract side effects of zidovudine with tenofovir plus emtric-itabine in West African adults with high CD4 counts. J Int AIDS Soc 2013; 16: 18059.
24. Messou E, Chaix ML, Gabillard D, et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on an-tiretroviral therapy in Côte d'Ivoire. J Ac-quir Immune Defic Syndr 2011; 56: 356-64.
25. Grinsztejn B, Hosseinipour MC, Rib-audo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014;14:281-90.
26. Gupta S, Granich R, Date A, et al. Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries. Int J Tuberc Lung Dis 2014;18:1149-58.
27. Getahun H, Granich R, Sculier D, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010;24:Suppl 5:S57-S65.
28. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 801-8.
29. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-57.
30. Pape J W, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-72.
31. Perriëns JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-in-fected patients in Zaire-a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-84.
32. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-98.
33. Charalambous S, Grant AD, Innes C, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010; 24: Suppl 5: S5-S13.
34. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 2014;384:682-90.
35. Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015;68:Suppl 3:S297-S305.
36. Yirdaw KD, Jerene D, Gashu Z, et al. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One 2014; 9(8): e 104557.
37. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009;23:631-6.
38. Durovni B, Saraceni V, Moulton LH, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013; 13: 852-8.
39. Kufa T, Mabuto T, Muchiri E, et al. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One 2014; 9(11): e111209.
40. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20.
41. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23: 1717-25.
42. Williams BG, Hargrove JW, Humphrey JH. The benefits of early treatment for HIV. AIDS 2010; 24: 1790-1.